Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة الرام للصناعات الدوائية - ram pharmaceutical industries co. ltd. - roxithromycin 150 mg - 150 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - roxithromycin, quantity: 300 mg - tablet, film coated - excipient ingredients: propylene glycol; povidone; colloidal anhydrous silica; hypromellose; titanium dioxide; sodium starch glycollate type b; sodium starch glycollate type a; maize starch; purified talc; hyprolose; glucose; magnesium stearate; poloxamer - adults: roxithromycin is indicated for the treatment of the following types of mild to moderately severe infections caused by or likely to be caused by susceptible microorganisms: upper respiratory tract infection: acute pharyngitis, tonsillitis and sinusitis. lower respiratory tract infection: acute bronchitis and acute exacerbations of chronic bronchitis; community acquired pneumonia. skin and skin structure infections. nongonococcal urethritis. appropriate culture and sensitivity tests should be performed when necessary to determine organism susceptibility and thus treatment suitability. therapy with roxithromycin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - roxithromycin -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - roxithromycin -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - roxithromycin, quantity: 300 mg - tablet, film coated - excipient ingredients: povidone; hyprolose; maize starch; poloxamer; colloidal anhydrous silica; purified talc; magnesium stearate; glucose; titanium dioxide; hypromellose; propylene glycol - adults: roxithromycin is indicated for the treatment of the following types of mild to moderately severe infections in adults caused by or likely to be caused by susceptible micro-organisms: upper respiratory tract infection: acute pharyngitis, tonsillitis, and sinusitis. lower respiratory tract infection: acute bronchitis and acute exacerbation of chronic bronchitis; community acquired pneumonia. skin and skin structure infections. non-gonococcal urethritis. children: roxithromycin 150 mg tablets are indicated for the treatment of the following mild to moderately severe infections in children weighing greater than 40 kg caused by or likely to be caused by susceptible micro-organisms: acute pharyngitis. acute tonsillitis. impetigo. appropriate culture and sensitivity tests should be performed when necessary to determine an organisms susceptibility and thus treatment suitability. therapy with roxithromycin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - roxithromycin 300mg;   - coated tablet - 300 mg - active: roxithromycin 300mg   excipient: colloidal silicon dioxide glucose hyprolose hypromellose magnesium stearate maize starch povidone propylene glycol purified talc titanium dioxide water

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

imeks pharma sdn. bhd. - roxithromycin -

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - roxithromycin 50mg - powder for oral suspension - 50 mg - active: roxithromycin 50mg excipient: arginine carmellose sodium colloidal silicon dioxide orange saccharin sucrose

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - roxithromycin 50mg - tablet - 50 mg - active: roxithromycin 50mg excipient: colloidal silicon dioxide glucose hypromellose   hypromellose phthalate magnesium stearate maize starch poloxamer povidone propylene glycol purified talc

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - roxithromycin 50mg - dispersible tablet - 50 mg - active: roxithromycin 50mg excipient: colloidal silicon dioxide crospovidone strawberry fumaric acid glycyrrhiza glabra macrogol 6000 magnesium stearate methacrylic acid copolymer microcrystalline cellulose purified talc saccharin sodium sodium hydroxide sodium laureth sulfate triethyl citrate